GW 274150

Drug Profile

GW 274150

Alternative Names: 274150; GSK 274150

Latest Information Update: 01 Jun 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiallergics; Antiasthmatics; Small molecules; Sulfides
  • Mechanism of Action Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease; Migraine; Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2006 Development discontinued for Rheumatoid arthritis during 2006
  • 30 Nov 2004 Phase-II clinical trials in Rheumatoid arthritis in United Kingdom (PO)
  • 28 May 2004 A study has been added to the Advances in the Treatment of Nausea and Migraine pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top